Retatrutide vs Mazdutide

Both retatrutide and mazdutide are investigational next-generation obesity drugs. Neither is FDA approved outside China. Retatrutide is a triple GLP-1/GIP/glucagon agonist developed by Eli Lilly; mazdutide (IBI362) is a dual GLP-1/glucagon agonist developed by Innovent Biologics. No head-to-head trial exists.

What Is Mazdutide?

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist developed by Innovent Biologics, primarily studied in Chinese populations. Phase 3 data showed approximately 14.5% weight loss at 36 weeks in adults with obesity. It is approved in China for type 2 diabetes management. It does not include GIP receptor agonism.

Key Differences